The second group, whose expression peaked at the early-MM disease stage (Fig. 2d), consisted of Il5ra, a cytokine receptor, Mgmt, a methyltransferase crucial for genome stability, and Tsc22d1, a pro-apoptotic tumour suppressor. Here, MGMT is linked to Miyoshi myopathy.